Literature DB >> 16920751

Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis.

O Distler, F Behrens, D Huscher, I Foeldvari, A Zink, P Nash, C P Denton, M Humbert, M Matucci-Cerinic, J Seibold, L Rubin, D E Furst.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16920751     DOI： 10.1093/rheumatology/kel273

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  3 in total

1.  Development of Clinical Trial Assessments for the Study of Interstitial Lung Disease in Patients who have Connective Tissue Diseases-Methodological Considerations.

Authors:  Dörte Huscher; Lesley Ann Saketkoo; David Pittrow; Dinesh Khanna
Journal:  Curr Rheumatol Rev       Date:  2010-05-01

Review 2.  Clinical trials and basic research: defining mechanisms and improving treatment in connective tissue disease.

Authors:  Lewis J Rubin; Carol M Black; Christopher P Denton; James R Seibold
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

3.  Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials.

Authors:  Lesley Ann Saketkoo; Shikha Mittoo; Dörte Huscher; Dinesh Khanna; Paul F Dellaripa; Oliver Distler; Kevin R Flaherty; Sid Frankel; Chester V Oddis; Christopher P Denton; Aryeh Fischer; Otylia M Kowal-Bielecka; Daphne LeSage; Peter A Merkel; Kristine Phillips; David Pittrow; Jeffrey Swigris; Katerina Antoniou; Robert P Baughman; Flavia V Castelino; Romy B Christmann; Lisa Christopher-Stine; Harold R Collard; Vincent Cottin; Sonye Danoff; Kristin B Highland; Laura Hummers; Ami A Shah; Dong Soon Kim; David A Lynch; Frederick W Miller; Susanna M Proudman; Luca Richeldi; Jay H Ryu; Nora Sandorfi; Catherine Sarver; Athol U Wells; Vibeke Strand; Eric L Matteson; Kevin K Brown; James R Seibold
Journal:  Thorax       Date:  2013-12-24       Impact factor: 9.139
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.